Q1 Preview: AstraZeneca’s Oncology Pipeline Center Stage As ASCO Approaches
Potential ASCO readouts and the recent setback for Fasenra in COPD will feature in AstraZeneca’s first quarter earnings presentation next week.
You may also be interested in...
AstraZeneca’s bid to expand its respiratory biologic Fasenra from asthma into the chronic obstructive pulmonary disease space has been hurt by a Phase III failure but the company is holding its horses until the results of another large late-stage trial come in before the end of this quarter.
AstraZeneca's novel targeted anticancer selumetinib has missed its endpoints in a Phase III study in lung cancer, the second late-stage failure for the product, which last year disappointed in uveal melanoma.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.